Join Lachman Consultants at GRx+Biosims™ 2023 in North Bethesda, MD, Oct 2 – 4 for three days of insights and engaging discussions around the most pressing issues vital to the generics and biosimilars industry. Lachman will be represented by several members of the team, including:

  • Frances Zipp, President & CEO
  • Bob Pollock, M.S., Outside Director of the Lachman Consultants Board of Directors
  • Jennifer Leaming, RAC, Principal Consultant
  • Martin Shimer, II, RPh, Executive Director, Regulatory Affairs
  • Matt Taylor, Director of Client Engagement

FDA experts will discuss current regulations, guidance, case law, and policies that impact the industry today, and share insights into how legislation related to the generics and biosimilars industry can influence patient access to more affordable medicines. Aimed at helping bench scientists and technical professionals better understand FDA expectations to make more informed decisions, the premier event is designed to foster collaborative dialogue between industry professionals, regulatory experts, and stakeholders to address challenges, explore new opportunities, and drive innovation in the generics and biosimilars sector.

On Wednesday, Oct. 4, Lachman Principal Consultant Jennifer Leaming, RAC, will co-host “What Can Industry and FDA do to Tackle Nitrosamine Impurities.” The 90-minute session will delve into the complexities surrounding the newly detected nitrosamine impurities, how the FDA and the industry can collaborate to tackle these challenges, and the scientific and policy implications of various approaches.

Join the Lachman team at booth 4 to engage in a two-way dialogue around regulatory affairs, challenges facing the generics and biosimilars industry, and emerging trends that are fueling advancements.

Don’t miss this opportunity to learn from and network with speakers, attendees, and exhibitors and gain valuable insights to power your professional development.

Click here to learn more or register.